Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Andreas M HohlbaumHendrik GilleStefan TrentmannMaria KolodziejczykBarbara RattenstetterCoby M LaarakkersGalina KatzmannHans Jürgen ChristianNicole AndersenAndrea AllersdorferShane A OlwillBernd MeibohmLaurent P AudolyDorine W SwinkelsRachel P L van SwelmPublished in: British journal of pharmacology (2018)
In conclusion, we developed a dose-dependent and safe approach for the direct suppression of hepcidin, resulting in prolonged iron mobilization to alleviate iron-restricted erythropoiesis that can address the root cause of ACD. PRS-080-PEG30 is currently in early clinical development.
Keyphrases